A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide. Etentamig is an invest

Trial Details

NCT ID
NCT07728188
Phase
PHASE3
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Etentamig
  • Pomalidomide
  • Daratumumab
  • Dexamethasone
  • Carfilzomib
  • Teclistamab
Locations (sample)
  • Ogden, Utah, United States|41.223,-111.97383
  • Jerusalem, Israel|31.76904,35.21633
  • Kyoto, Kyoto, Japan|35.02107,135.75385
  • Natori-shi, Miyagi, Japan|38.16667,140.88333
  • Bunkyo Ku, Tokyo, Japan

Key Eligibility Criteria

  • Diagnosis of relapsed or refractory (RR) multiple myeloma (MM).
  • Prior treatment with at least one and no more than three prior lines of therapy, including lenalidomide.
  • Adequate organ function and performance status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →